{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:25:15Z","timestamp":1794317115948,"version":"4.9.0"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ajo.2026.10.008","type":"journal-article","created":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T14:16:48Z","timestamp":1792333008000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to Comment on: Evaluation of the Impact of Gamma-Aminobutyric Acid on Diabetic Retinopathy in a Large US Population-Based Cohort"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0458-4181","authenticated-orcid":false,"given":"Katherine E.","family":"Talcott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4827-6906","authenticated-orcid":false,"given":"Sonia B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ajo.2026.10.008_bib0001","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/archophthalmol.2009.308","article-title":"Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial comparing Intravitreal Triamcinolone with focal\/grid photocoagulation","volume":"127","author":"Bressler","year":"2009","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2026.10.008_bib0002","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archophthalmol.2012.1043","article-title":"Long-term effects of ranibizumab on diabetic retinopathy severity and progression","volume":"130","author":"Ip","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2026.10.008_bib0003","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-93384-5","article-title":"Risk factors associated with progression of diabetic retinopathy in eyes treated with panretinal photocoagulation","volume":"11","author":"Baek","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ajo.2026.10.008_bib0004","doi-asserted-by":"crossref","first-page":"P75","DOI":"10.1016\/j.ophtha.2024.12.020","article-title":"Diabetic Retinopathy Preferred Practice Pattern\u00ae","volume":"132","author":"Lim","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2026.10.008_bib0005","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ajo.2025.02.025","article-title":"The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy","volume":"274","author":"Abbass","year":"2025","journal-title":"Am J Ophthalmol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426005647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939426005647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:42:37Z","timestamp":1794314557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939426005647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":5,"alternative-id":["S0002939426005647"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2026.10.008","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to Comment on: Evaluation of the Impact of Gamma-Aminobutyric Acid on Diabetic Retinopathy in a Large US Population-Based Cohort","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2026.08.052","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}